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Modified protocols of two rapid tests were compared with a less sensitive (LS) (detuned) enzyme immuno-
assay (EIA) for their abilities to distinguish recent human immunodeficiency virus (HIV) seroconversion from
long-term infections. The results for samples from 100 HIV-positive patient that had previously been tested by
the Vironostika LS EIA had a 97% concordance with the results of the Determine HIV 1/2 assay and 93%
concordance with those of the OraQuick HIV 1/2 assay.
The monitoring of individuals for determination of the in-
cidence of human immunodeficiency virus (HIV) infection is
important for public health surveillance and prevention pro-
grams. The less sensitive (LS) enzyme immunoassay (EIA) (or
the serologic testing algorithm for recent HIV seroconversion
[STARHS]) has made possible the serologic diagnosis of inci-
dent HIV infection in individual patients as well as estimation
of the incidence of HIV in populations (1–3, 5). The Vironos-
tika LS EIA has been validated by the U.S. Centers for Disease
Control and Prevention (CDC) and is now widely applied in
the United States and internationally to estimate the incidence
of HIV type 1 (HIV-1) and to recruit subjects with early HIV
infection into clinical trials. However, the Vironostika LS EIA
is no longer available as of April 2008, according to the man-
ufacturer. Therefore, a replacement assay will need to come
from one of the currently available HIV-1/2 assays or a new
assay will need to be developed for estimation of the incidence
of HIV-1/2 infections.
Advances in HIV diagnostic technologies have resulted in
the development of simple rapid tests (RTs) for antibody de-
tection. We compared two RTs (the Determine HIV-1/2 assay
[Abbott Laboratories, Abbott Park, IL] and the OraQuick
Advance HIV-1/2 assay [OraSure Technologies, Inc., Bethle-
hem, PA]), modified as suggested by the CDC (6) to the
Vironostika LS EIA (bioMerieux Inc, Durham, NC), using 100
consecutive samples submitted for assessment of clinical trial
eligibility. STARHS was performed with confirmed HIV-pos-
itive serum samples by following standard CDC protocols and
the algorithm for the Vironostika LS EIA. The Vironostika LS
EIA is a second-generation assay that uses a viral lysate as the
capture antigen. The Determine HIV-1/2 assay uses HIV-1
synthetic peptide gp41 and recombinant antigens gp41 and
gp120, HIV-2 synthetic peptide gp36 and recombinant antigen
gp36, and HIV-1 subtype O recombinant antigens gp41 and
gp120. The antigens used in the OraQuick assay are synthetic
peptides representing the HIV envelope region.
To identify persons recently infected with HIV, STARHS
uses the modified protocol of the FDA-approved standard EIA
by increasing the specimen dilution and decreasing the sample
volume and substrate incubation times to render the assay less
sensitive. The Vironostika LS EIA detects HIV infection ap-
proximately 170 days (95% confidence interval  163 to 183
days) after the initial infection by using a standard optical
density (SOD) cutoff of 1.0. A blood sample that is reactive
by a sensitive EIA and that is positive by Western blotting but
nonreactive by the LS EIA (with a value less than or equal to
the SOD cutoff) identifies a person in the period of early HIV
infection, when the antibody titer is increasing but has not
peaked. We were using the Vironostika LS EIA to determine
eligibility for a clinical trial that required HIV-infected indi-
viduals with recent infection (6 months from seroconver-
sion); for that clinical trial, we used an SOD cutoff of 0.75 to
minimize the likelihood that people with established infection
would be enrolled in the trial.
Both RTs are manually performed, visually read, qualitative
immunoassays for the detection of antibodies to HIV-1 and
HIV-2 in human serum, plasma, or whole blood. For the De-
termine HIV-1/2 LS assay, the samples were diluted in two
steps: 5 l of sample was diluted in 195 l of whole plasma
from a healthy individual plus (1:40), followed by a second
dilution of 10 l into 240 l of pooled true human serum
(SeraCare Life Sciences, Milford, MA), for a final dilution of
1:1,000. A 50-l aliquot of this final dilution was applied di-
rectly to the fibrous pad of the test strip, and the test was
visually read after 15 min of incubation at room temperature.
For the OraQuick HIV-1/2 LS assay, the predilution was
achieved by adding 5 l of specimen to 195 l of pooled true
human serum (1:40). Twenty microliters of the prediluted
specimen was added to 800 l of OraQuick Advance Rapid
HIV-1/2 assay buffer (200 l was removed from 1 ml buffer,
and 20 l of the prediluted sample was added to achieve final
dilution of 1:1,640). To ensure the precision of the sample
dilutions, the volumes were measured with precision pipettes
in place of the loops supplied with the kits. The Flat-Pad device
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from the kit was then inserted into the vial, and the test result
was read after 20 min of incubation at room temperature.
The results of both the RTs were read as described in the
manufacturer’s package insert. They were scored as nonreac-
tive, weakly reactive, and reactive. Samples with no visual band
were classified as nonreactive and were reported as recent
seroconversions. The samples with a light band were classified
as weakly reactive, and those with a definite band were classi-
fied as reactive; however, both weakly reactive and reactive
samples were reported as being from individuals with long-
term infections. The results obtained with 100 samples that had
previously been tested by the Vironostika LS EIA are shown in
Table 1. Overall, the results of the Determine HIV-1/2 LS test
had 97% concordance with the results of the Vironostika LS
EIA, while the results of the OraQuick LS assay gave a con-
cordance of 93% (Table 1). The three discordant samples
found in the Determine HIV-1/2 LS (detuned) assays had
Vironostika LS EIA SODs that ranged from 1.006 to 1.516
(Table 2). In contrast, the six falsely nonreactive specimens
found by the less sensitive OraQuick LS assay had Vironostika
LS EIA SODs that ranged from 1.022 to 6.208. Two specimens
(specimens D and E) were nonreactive by both detuned RTs
but scored reactive by the Vironostika LS EIA, with SODs of
1.516 and 1.107, respectively. One specimen had a falsely re-
active OraQuick LS (detuned) assay result, although the Vi-
ronostika LS EIA SOD was only 0.583. It has previously been
reported that the Determine HIV-1/2 RT is more sensitive
than some of the other RTs (4).
Our results suggest that the Determine HIV-1/2 LS assay
would give results that are more comparable to those of the
Vironostika LS EIA than the OraQuick LS assay would for the
identification of recent infections. These RTs provide results in
minutes, use minimal laboratory equipment, and have been
used in resource-limited settings. The Determine HIV-1/2 as-
say is approved for use internationally but not in the United
States, whereas the OraQuick Advance Rapid HIV-1/2 assay is
approved by the FDA for use in the United States.
Application of these effective RTs for the identification of
recent HIV seroconversion will likely facilitate studies de-
signed to derive incidence estimates in different parts of the
world, especially in resource-limited settings. One drawback of
the use of RTs tests for the estimation of recent infection for
surveillance purposes is that they do not lend themselves to
high-throughput testing. Because these RTs for the detection
of HIV are easy to use, they are sometimes performed by
personnel with limited or no formal laboratory training. These
modified LS assays should be performed by trained laboratory
personnel, as they involve serial dilution of the samples with
precision pipettes, visual scoring of the bands, and interpreta-
tion of the results. Standardization of RTs for the detection of
HIV as a tool to estimate the incidence of HIV will require
additional studies.
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TABLE 1. Concordance between Vironostika LS EIA and
modified LS RTs
Assay, result
No. of samples with the indicated reactivity by the
following assaya:
Determine HIV-1/2
LS assay OraQuick assay
Reactive Nonreactive Reactive Nonreactive
Vironostika LS EIA,
reactive
66 3 63 6
Vironostika LS EIA,
nonreactive
0 31 1 30
a Reactive indicates a long-term infection, and nonreactive indicates a recent
seroconversion.
TABLE 2. Details of the discordant results found by testing for













A 6.208 R R NR
B 2.292 R R NR
C 1.660 R R NR
D 1.516 R NR NR
E 1.107 R NR NR
F 1.022 R R NR
G 1.006 R NR R
H 0.583 NR NR R
a R, reactive, which indicates a long-term infection; NR, nonreactive, which
indicates a recent seroconversion.
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